<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68769">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01837940</url>
  </required_header>
  <id_info>
    <org_study_id>2012/309</org_study_id>
    <nct_id>NCT01837940</nct_id>
  </id_info>
  <brief_title>Efficacy of a Dietary Supplementation With Lactobacillus Reuteri for Digestive Health in an Elderly Population</brief_title>
  <official_title>Efficacy of a Dietary Supplementation With Lactobacillus Reuteri DSM 17938 for Digestive Health in an Elderly Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Örebro University, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioGaia AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Örebro University, Sweden</source>
  <oversight_info>
    <authority>Sweden: The ethical review board; Regionala etikprövningsnämnden i Uppsala</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of a daily supplement consisting of
      the probiotic bacteria, Lactobacillus reuteri, on the digestive health among persons 65
      years and older.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall purpose of the study is to investigate the effect of daily supplementation,
      during a three months period, of L. reuteri on digestive health in an elderly Swedish
      population, residing in the municipality of Örebro. In addition an extensive screening of
      the study population in regard of overall health status, functionality and well-being as
      well as the composition of the gut microbiome will be assessed prior study start through the
      collection of baseline data
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline Gastrointestinal symptoms to 3months</measure>
    <time_frame>Baseline, at 2 months and at 3months/study end</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gastrointestinal discomfort will be assessed through the gastrointestinal symptoms rating score (GSRS), a clinical rating scale for gastrointestinal symptoms. The GSRS includes 15 symptoms and uses a 7-point Likert scale in which 1 represents the most positive option and 7 the most negative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in use of intestinal motility regulating substances during the 3-month intervention period</measure>
    <time_frame>at baseline and end of study ( 3months)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Intestinal motility regulating substances (e.g anti-diarrheal and anti-constipation medication)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in mood during the 3month intervention period</measure>
    <time_frame>at baseline, 2months and 3monts/study end</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mood changes will be assessed through the questionnaire hospital anxiety and depression scale (HADs)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in quality of life during the 3-month intervention period</measure>
    <time_frame>at baseline, at baseline, 2months and 3monts/study end</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life will be assessed through the EuroQol questionnaire.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Constipation</condition>
  <condition>Diarrhea</condition>
  <condition>Indigestion</condition>
  <condition>Reflux</condition>
  <condition>Abdominal Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dietary supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactobacillus reuteri DSM 17938</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Galactooligosaccharide (GOS) and rhamnose in a powder formulation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus reuteri DSM 17938</intervention_name>
    <description>Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation</description>
    <arm_group_label>dietary supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 65 years

          -  Informed consent signed by study participant or legal guardian

        Exclusion Criteria:

          -  Known gastrointestinal disease, with strictures, malignance's and ischemia.

          -  Inflammatory bowel diseases (IBD)

          -  Participation in other clinical trials in the past three months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Jan Brummer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Örebro Universitet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Örebro University</name>
      <address>
        <city>Örebro</city>
        <state>Närke</state>
        <zip>701 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 23, 2013</lastchanged_date>
  <firstreceived_date>March 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Örebro University, Sweden</investigator_affiliation>
    <investigator_full_name>Robert Brummer</investigator_full_name>
    <investigator_title>Professor and Dean</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abdominal Pain</mesh_term>
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
